Vistagen Therapeutics Inc (NASDAQ:VTGN) shares, rose in value on Wednesday, June 18, with the stock price down by -13.45% to the previous day’s close as strong demand from buyers drove the stock to $2.06.
Actively observing the price movement in the last trading, the stock closed the session at $2.38, falling within a range of $2.05 and $2.3533. The value of beta (5-year monthly) was 0.687. Referring to stock’s 52-week performance, its high was $4.21, and the low was $1.90. On the whole, VTGN has fluctuated by -19.06% over the past month.
With the market capitalization of Vistagen Therapeutics Inc currently standing at about $59.45 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Jun-02.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 215.67k.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that VTGN’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of VTGN currently trading nearly -13.64% and -10.57% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 35.75, while the 7-day volatility ratio is showing 8.94% which for the 30-day chart, stands at 4.46%. Furthermore, Vistagen Therapeutics Inc (VTGN)’s beta value is 0.69, and its average true range (ATR) is 0.16.
A comparison of Vistagen Therapeutics Inc (VTGN) with its peers suggests the former has fared considerably weaker in the market. VTGN showed an intraday change of -13.45% in last session, and over the past year, it shrunk by -41.48%%.
Data on historical trading for Vistagen Therapeutics Inc (NASDAQ:VTGN) indicates that the trading volumes over the past 10 days have averaged 0.18 and over the past 3 months, they’ve averaged 135.64K. According to company’s latest data on outstanding shares, there are 28.32 million shares outstanding.
Nearly 9.53% of Vistagen Therapeutics Inc’s shares belong to company insiders and institutional investors own 46.46% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.53 million shares as on 2025-05-30, resulting in a short ratio of 3.69. According to the data, the short interest in Vistagen Therapeutics Inc (VTGN) stood at 273.00 of shares outstanding as of 2025-05-30; the number of short shares registered in 2025-04-30 reached 0.48 million. The stock has fallen by -30.17% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the VTGN stock heading into the next quarter.
